Pharnext’s investigational oral combination therapy PXT864 prevents degeneration of motor neurons and their point of contact with muscle cells, as well as the buildup of toxic TDP-43 protein aggregates — all hallmarks of amyotrophic lateral sclerosis (ALS) — in cellular models of the disease. - https://alsnewstoday.com/2020/08/27/...aign=OneSignal
- Welcome to the MND Association Forum.
If this is your first visit, be sure to check out the Forum Guidelines. You will need to Register before you can post. All registrations are manually approved by the Forum Admin team to try and help prevent spam so there may be a slight delay between registering and being able to post.
To start viewing posts, select the section of the forum that you want to visit from the selection below.